Order Article Reprints

Di Muro G, Mangili F, Esposito E, Barbieri AM, Catalano R, Treppiedi D, Marra G, Nozza E, Lania AGA, Ferrante E, et al. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells. Cancers. 2023; 15(12):3218. https://doi.org/10.3390/cancers15123218

Di Muro, Genesio, Federica Mangili, Emanuela Esposito, Anna Maria Barbieri, Rosa Catalano, Donatella Treppiedi, Giusy Marra, Emma Nozza, Andrea G. A. Lania, Emanuele Ferrante, and et al. 2023. "A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells" Cancers 15, no. 12: 3218. https://doi.org/10.3390/cancers15123218

Di Muro, G., Mangili, F., Esposito, E., Barbieri, A. M., Catalano, R., Treppiedi, D., Marra, G., Nozza, E., Lania, A. G. A., Ferrante, E., Locatelli, M., Arosio, M., Peverelli, E., & Mantovani, G. (2023). A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells. Cancers, 15(12), 3218. https://doi.org/10.3390/cancers15123218